Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Dyslipidemia

Free Subscription Articles published in Curr Opin Lipidol Retrieve available abstracts of 48 articles: HTML format Text format

Single Articles

August 2017
1. NEMES K, Aberg F
   Interpreting lipoproteins in nonalcoholic fatty liver disease.
   Curr Opin Lipidol. 2017;28:355-360.
   PubMed     Text format     Abstract available
   
   
   July 2017
2. BADIMON L, Padro T, Cubedo J
   Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome.
   Curr Opin Lipidol. 2017 Jul 5. doi: 10.1097/MOL.0000000000000441.
   PubMed     Text format     Abstract available
   
   
   June 2017
3. PAALVAST Y, de Boer JF, Groen AK
   Developments in intestinal cholesterol transport and triglyceride absorption.
   Curr Opin Lipidol. 2017;28:248-254.
   PubMed     Text format     Abstract available
   
   
   April 2017
4. GRAHAM CA, Latten MJ, Hart PJ
   Molecular diagnosis of familial hypercholesterolaemia.
   Curr Opin Lipidol. 2017 Apr 29. doi: 10.1097/MOL.0000000000000430.
   PubMed     Text format     Abstract available
   
   
   
5. MARTIN AC, Bell DA, Brett T, Watts GF, et al
   Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies.
   Curr Opin Lipidol. 2017 Apr 19. doi: 10.1097/MOL.0000000000000423.
   PubMed     Text format     Abstract available
   
   
   
6. BURKE AC, Huff MW
   ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
   Curr Opin Lipidol. 2017;28:193-200.
   PubMed     Text format     Abstract available
   
   
   
7. ARSENAULT BJ, Perrot N, Couture P
   Does lifestyle contribute to disease severity in patients with inherited lipid disorders?
   Curr Opin Lipidol. 2017;28:177-185.
   PubMed     Text format     Abstract available
   
   
   March 2017
8. CALANDRA S, Tarugi P, Bertolini S
   Impact of rare variants in autosomal dominant hypercholesterolemia causing genes.
   Curr Opin Lipidol. 2017 Mar 18. doi: 10.1097/MOL.0000000000000414.
   PubMed     Text format     Abstract available
   
   
   February 2017
9. KINDT I, Mata P, Knowles JW
   The role of registries and genetic databases in familial hypercholesterolemia.
   Curr Opin Lipidol. 2017 Feb 6. doi: 10.1097/MOL.0000000000000398.
   PubMed     Text format     Abstract available
   
   
   
10. BOURBON M, Alves AC, Sijbrands EJ
    Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2017 Feb 6. doi: 10.1097/MOL.0000000000000404.
    PubMed     Text format     Abstract available
    
    
    
11. HOPKINS PN, Lane SR
    Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns.
    Curr Opin Lipidol. 2017 Feb 2. doi: 10.1097/MOL.0000000000000397.
    PubMed     Text format     Abstract available
    
    
    
12. TAHER J, Farr S, Adeli K
    Central nervous system regulation of hepatic lipid and lipoprotein metabolism.
    Curr Opin Lipidol. 2017;28:32-38.
    PubMed     Text format     Abstract available
    
    
    
13. BJORNSON E, Adiels M, Taskinen MR, Boren J, et al
    Kinetics of plasma triglycerides in abdominal obesity.
    Curr Opin Lipidol. 2017;28:11-18.
    PubMed     Text format     Abstract available
    
    
    January 2017
14. SANTOS RD
    Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?
    Curr Opin Lipidol. 2017 Jan 5. doi: 10.1097/MOL.0000000000000391.
    PubMed     Text format     Abstract available
    
    
    December 2016
15. HOPKINS PN
    Genotype-guided diagnosis in familial hypercholesterolemia: population burden and cascade screening.
    Curr Opin Lipidol. 2016 Dec 24. doi: 10.1097/MOL.0000000000000388.
    PubMed     Text format     Abstract available
    
    
    
16. NORMAN R, Watts GF, Weintraub W, Gidding SS, et al
    Challenges in the health economics of familial hypercholesterolemia.
    Curr Opin Lipidol. 2016;27:563-569.
    PubMed     Text format     Abstract available
    
    
    August 2016
17. HARALAMBOS K, Ashfield-Watt P, McDowell IF
    Diagnostic scoring for familial hypercholesterolaemia in practice.
    Curr Opin Lipidol. 2016;27:367-374.
    PubMed     Text format     Abstract available
    
    
    April 2016
18. GENCER B, Nanchen D
    Identifying familial hypercholesterolemia in acute coronary syndrome.
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available
    
    
    
19. BOGSRUD MP, Ulven SM, Holven KB
    Does intrauterine exposure to hypercholesterolemia adversely affect familial hypercholesterolemia phenotype?
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available
    
    
    
20. MUNDAL L, Retterstol K
    A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries.
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available
    
    
    
21. HIGGINS CA, Rees A
    Do the mechanisms by which LDL-c levels are reduced influence the extent of clinical benefit which subsequently accrues?
    Curr Opin Lipidol. 2016;27:207-8.
    PubMed     Text format    
    
    
    
22. STENDER S, Tybjaerg-Hansen A
    Using human genetics to predict the effects and side-effects of drugs.
    Curr Opin Lipidol. 2016;27:105-11.
    PubMed     Text format     Abstract available
    
    
    
23. GHAZALPOUR A, Cespedes I, Bennett BJ, Allayee H, et al
    Expanding role of gut microbiota in lipid metabolism.
    Curr Opin Lipidol. 2016;27:141-7.
    PubMed     Text format     Abstract available
    
    
    
24. GAUDET D
    Novel therapies for severe dyslipidemia originating from human genetics.
    Curr Opin Lipidol. 2016;27:112-24.
    PubMed     Text format     Abstract available
    
    
    February 2016
25. FARR S, Taher J, Adeli K
    Central nervous system regulation of intestinal lipid and lipoprotein metabolism.
    Curr Opin Lipidol. 2016;27:1-7.
    PubMed     Text format     Abstract available
    
    
    December 2015
26. BRAHM AJ, Hegele RA
    Combined hyperlipidemia: familial but not (usually) monogenic.
    Curr Opin Lipidol. 2015.
    PubMed     Text format     Abstract available
    
    
    
27. SIJBRANDS EJ, Nieman K, Budoff MJ
    Cardiac computed tomography imaging in familial hypercholesterolaemia: implications for therapy and clinical trials.
    Curr Opin Lipidol. 2015;26:586-92.
    PubMed     Text format     Abstract available
    
    
    
28. GRYN SE, Hegele RA
    Novel therapeutics in hypertriglyceridemia.
    Curr Opin Lipidol. 2015;26:484-91.
    PubMed     Text format     Abstract available
    
    
    
29. WIERZBICKI AS, Watts GF
    The hinterland of familial hypercholesterolaemia: what do we not know?
    Curr Opin Lipidol. 2015;26:475-83.
    PubMed     Text format     Abstract available
    
    
    October 2015
30. BURKHARDT R
    Hyperlipidemia and cardiovascular disease: reinforcement for 'lower is better'.
    Curr Opin Lipidol. 2015;26:468-9.
    PubMed     Text format    
    
    
    June 2015
31. RYAN A, Byrne CD
    Importance of early recognition of heterozygous familial hypercholesterolaemia.
    Curr Opin Lipidol. 2015.
    PubMed     Text format     Abstract available
    
    
    
32. SJOUKE B, Hovingh GK, Kastelein JJ, Stefanutti C, et al
    Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.
    Curr Opin Lipidol. 2015;26:200-9.
    PubMed     Text format     Abstract available
    
    
    
33. YEANG C, Witztum JL, Tsimikas S
    'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering.
    Curr Opin Lipidol. 2015;26:169-78.
    PubMed     Text format     Abstract available
    
    
    
34. TAYLOR BA, Thompson PD
    Muscle-related side-effects of statins: from mechanisms to evidence-based solutions.
    Curr Opin Lipidol. 2015;26:221-7.
    PubMed     Text format     Abstract available
    
    
    
35. BRAAMSKAMP MJ, Hutten BA, Wiegman A
    Early initiation of statin treatment in children with familial hypercholesterolaemia.
    Curr Opin Lipidol. 2015;26:236-9.
    PubMed     Text format     Abstract available
    
    
    
36. REINER Z
    A comparison of European and US guidelines for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2015;26:215-20.
    PubMed     Text format     Abstract available
    
    
    
37. QURESHI N, Minhas R, Wierzbicki AS
    Prioritizing health outcomes in a limited world: writing lipid guidelines.
    Curr Opin Lipidol. 2015;26:188-94.
    PubMed     Text format     Abstract available
    
    
    
38. ROBINSON JG
    Statins and diabetes risk: how real is it and what are the mechanisms?
    Curr Opin Lipidol. 2015;26:228-35.
    PubMed     Text format     Abstract available
    
    
    
39. CHRISTOFFERSEN M, Tybjaerg-Hansen A
    Novel genes in LDL metabolism--a comprehensive overview.
    Curr Opin Lipidol. 2015;26:179-87.
    PubMed     Text format     Abstract available
    
    
    
40. WATERS DD
    LDL-cholesterol lowering and renal outcomes.
    Curr Opin Lipidol. 2015;26:195-9.
    PubMed     Text format     Abstract available
    
    
    April 2015
41. PEARS R, Griffin M, Futema M, Humphries SE, et al
    Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2015.
    PubMed     Text format     Abstract available
    
    
    
42. LU H, Daugherty A
    Atherosclerosis: cell biology and lipoproteins.
    Curr Opin Lipidol. 2015;26:152-3.
    PubMed     Text format    
    
    
    
43. HEGELE RA, Ban MR, Cao H, McIntyre AD, et al
    Targeted next-generation sequencing in monogenic dyslipidemias.
    Curr Opin Lipidol. 2015;26:103-13.
    PubMed     Text format     Abstract available
    
    
    
44. LANGE LA, Willer CJ, Rich SS
    Recent developments in genome and exome-wide analyses of plasma lipids.
    Curr Opin Lipidol. 2015;26:96-102.
    PubMed     Text format     Abstract available
    
    
    
45. COLE CB, Nikpay M, McPherson R
    Gene-environment interaction in dyslipidemia.
    Curr Opin Lipidol. 2015;26:133-8.
    PubMed     Text format     Abstract available
    
    
    February 2015
46. SACKS FM
    The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia.
    Curr Opin Lipidol. 2015;26:56-63.
    PubMed     Text format     Abstract available
    
    
    June 2014
47. FILIPPOV S, Pinkosky SL, Newton RS
    LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase.
    Curr Opin Lipidol. 2014.
    PubMed     Text format     Abstract available
    
    
    
48. TALMUD PJ, Futema M, Humphries SE
    The genetic architecture of the familial hyperlipidaemia syndromes: rare mutations and common variants in multiple genes.
    Curr Opin Lipidol. 2014.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: